Stock message boards
MNV
Market News Video
MNV MNV 10 Stocks Crossing Below Book Value
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

T Rowe Price Group Becomes #102 Most Shorted S&P 500 Component, Replacing Bristol-Myers Squibb
Monday, October 27, 3:49 PM ET, by Market News Video Staff

The most recent short interest data has been released by the NASDAQ for the 10/15/2014 ...

Bristol-Myers Squibb Popular Amongst Latest 13F Filers
Thursday, October 30, 10:03 AM ET, by Market News Video Staff

At Holdings Channel, we have reviewed the latest batch of the 26 most recent 13F ...

Thursday Sector Leaders: Utilities, Healthcare
Thursday, October 30, 2:35 PM ET, by Market News Video Staff

Looking at the sectors faring best as of midday Thursday, shares of Utilities companies are ...

Bristol-Myers Squibb a Top 25 Dividend Giant With 2.45% Yield (BMY)
Friday, October 31, 9:17 AM ET, by Market News Video Staff

Bristol-Myers Squibb Co. (BMY) has been named as a Top 25 ''Dividend Giant'' by ETF ...

PFE Crosses Above Key Moving Average Level
Friday, October 31, 11:37 AM ET, by Market News Video Staff

In trading on Friday, shares of Pfizer Inc (PFE) crossed above their 200 day moving ...

  More articles:  1 2 3 4 5 6 7 next »

Bristol-Myers, Pfizer Announce Positive Results; An FDA Approval for Pfizer

By Market News Video Staff, Monday, August 29, 8:47 AM ET
Play Video: The Importance of ETFs


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) announced over the weekend positive results in a Phase 3 trial that compared Elquis to warfarin for the prevention of stroke or systemic embolism in patients with atrial fibrillation and at least one risk factor for stroke.

The companies said the drug showed Elquis significantly reduced the risk of stroke or systemic embolism by 21%, major bleeding by 31%, and mortality by 11%. Separately, Pfizer said that the Food and Drug Administration has approved Xalkori capsules, which the company calls the first-ever drug targeting anaplastic lymphoma kinase, or ALK, for the treatment of locally advanced or metastatic non-small cell lung cancer that is ALK-positive.

Pfizer noted that lung cancer is responsible for more deaths each years worldwide than any other type of cancer, and the drug offers a new treatment option for a subset of patients with the disease.

The FDA gave the drug accelerated approval, and Pfizer is conducting post-marketing clinical trials to further evaluate its clinical benefit. Pfizer partnered with Abbott Laboratories’ (NYSE:ABT) Molecular business on a diagnostic test for ALK, which was approved simultaneously with the drug. Xalkori is available immediately through some pharmacies.


Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   Abbott   Definition   Earnings   Elquis   Food   Molecular   Mortgage   Myers   NYSE   Pfizer   Price   Rate   Witching   Xalkori   approved   atrial   benefit   business   cancer   capsules   clinical   compared   diagnostic   disease   drug   each   embolism   further   least   lung   lymphoma   marketing   mortality   over   patients   positive   risk   said   small   some   stroke   subset   systemic   targeting   that   treatment   which   with   worldwide   years
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Portfolio Channel Stock Market Definitions
MNV

Bristol-Myers, Pfizer Announce Positive Results; An FDA Approval for Pfizer | Market News Video | Copyright © 2008 - 2014, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.